Navigation Links
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard,of Care in Second Line Treatment of Small Cell Lung Cancer

s to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippon Kayaku, a Japanese pharmaceutical firm focused on oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of Amrubicin.

About Small Cell Lung Cancer

Small cell lung cancer is a disease in which malignant cells form in the tissues of the lung, and which occurs almost exclusively in people who smoke. While small cell lung cancer constitutes approximately 15 percent of all lung cancers, SCLC tends to be more aggressive and fast growing than the more common non-small cell lung cancer. Of the estimated 65,000 patients diagnosed with SCLC each year in the US and EU, approximately 60 percent of patients have extensive disease at diagnosis, and the remaining 40 percent present with localized, or limited stage, disease.

About Pharmion

Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic drug, Vidaza(R), a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This release contains forward-looking statements, including summary statements relating to the interim or preliminary results of clinical trials involving Amrubicin. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause the final results to differ significantly from the results sum
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
2. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
3. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
4. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
5. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
6. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
7. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
8. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
9. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
10. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
11. New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging
Post Your Comments:
(Date:8/22/2014)... Aug. 22, 2014  As the Medical Affairs, role ... leaders in this area are exploring methods to develop ... Medical Affairs Consortium at Best Practices, LLC is designed ... insights about the key challenges they face. The consortium ... through three virtual roundtable discussions where leaders discuss key ...
(Date:8/22/2014)...  Dr. Mark Rasak , MD is recognized ... Award in the field of Medicine as a result ... Dr. Rasak has over 15 years of ... the business; overseeing the daily operations; interventional cardiology; complex ... addition, he is an honored Fellow of the American ...
(Date:8/22/2014)... --  Zacks Equity Research highlights Epizyme (Nasdaq: EPZM - ... (Nasdaq: PNRA - Free Report ) as the Bear of ... Therapeutics (Nasdaq: FOLD - Free Report ), Sanofi (NYSE: ... Free Report ). Here is a synopsis of all ... The biotech bull market is far from over ...
Breaking Medicine Technology:Best Practices' Medical Affairs Consortium Survey Has Achieved Strong Participation 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6
... Althea Technologies, Inc., a leading provider of development ... its inaugural Health and Wellness Fair today. The fair ... daily activities to promote physical and mental health amongst ... encouraged to participate in daily challenges and talks. Today,s ...
... 2011 Delcath Systems, Inc. (NASDAQ: DCTH ) ... Life Sciences Management Access Conference on Tuesday, August 16, 2011 ... Financial Officer, will provide an overview of the Company,s business ... this conference is by invitation only. Delcath will offer a ...
Cached Medicine Technology:Althea Technologies Hosts Health and Wellness Week 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 2Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011 3
(Date:8/22/2014)... August 22, 2014 Today, Zane Benefits, ... guide on Account-Based Health Plans. , According to Zane ... a strategy to lower the cost of healthcare without ... medical spending accounts, however, can be confusing. , The ... learn the four main types of ABHPs. It also ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market by ... Kits (Isolation, Purification), By Application (Genomics, Proteomics), by ... 2018" This market was valued at $4,254.8 million ... a CAGR of 5.9% from 2013 to 2018, ... 98 market data Tables and 23 Figures spread ...
(Date:8/22/2014)... Recently, iFitDress.com, a well-known wedding dress manufacturer and ... wedding gowns . In addition to this, the company’s ... are provided with low shipping fees. , He ... new wedding gowns. In our online store, there are ... choose from. What’s more, all of them are extremely ...
(Date:8/22/2014)... 2014 (HealthDay News) -- Many Americans know little about how ... of an outbreak in the United States, a new survey ... worried that there will be a major Ebola outbreak in ... an immediate family member will get sick with the deadly ... School of Public Health poll. However, those opinions don,t ...
(Date:8/22/2014)... NV (PRWEB) August 22, 2014 Mi40x ... uses university-proven research to show people how they can use ... muscle in only a matter of weeks has caught the ... “Ben Pakulski is one of the most well-known bodybuilders in ... the body he has today, that in itself is a ...
Breaking Medicine News(10 mins):Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Discounted Wedding Gowns For Sale At Leading Online Shop iFitDress.com 2Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Mi40x: Review Exposes Ben Pakulski’s Guide to Packing on Lean Muscle Fast 2
... a medical device company focused on the treatment of ... Chief,Executive Officer, and Gregory J. Tibbitts, Chief Financial Officer, ... Growth Conference in,New York, NY on Thursday, September 20, ... A live Web cast and recording of the ...
... Sept. 17 John Brooke, General Manager of,Billian,s ... speaking at Dreamforce ,07 Global Gathering, Salesforce.com,s 5th,Annual ... week. Dreamforce is the ultimate gathering of ... base of Salesforce and AppExchance,users spanning industries, roles ...
... commonly used measure for pain screening may only be modestly ... Medicine and the University of North Carolina. In a study ... General Internal Medicine, they evaluate the usefulness of a scale ... pain from 0 (no pain) to 10 (worst pain). ...
... Opening of the 62nd United Nations General Assembly Tomorrow, September ... ... people dying,of hunger every day and governments failing to meet their millennium,commitment to ... food and hunger to play a,central role "on the table" of the 62nd ...
... 17, 2007) Contrary to concerns that restricting work ... patient care or the residents education, a study in ... College of Surgeons found that limiting work hours does ... addition, the study found that the new model improved ...
... Association,Inc. ("SMART"), announced today that it has become ... a not-for-profit, multi-industry,association working to stimulate the understanding, ... The Smart Card Alliance is the sole ... on the impact and value of Smart,cards in ...
Cached Medicine News:Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Rating your pain from 0 to 10 might not help your doctor 2Health News:HungerFREE Campaign Tells UN: 'Put food on the table' 2Health News:Study finds limiting work hours for surgical residents enhances training 2Health News:SMART Association Becomes 'Healthcare Council Member' of Smart Card Alliance 2
... is a monoclonal antibody based ... confirmatory identification of Neisseria gonorrhoeae. ... isolated, viable or fresh cultures. ... two minute rotation, a positive ...
Rapid Test Kit...
... The InTray™ GC is a ... detection of both Neisseria gonorrhoeae and ... a long shelf life and is ... system. Simply inoculate, incubate and ...
OneStep Strip Style Gonorrhea Test is a rapid direct binding test for the visual detection of gonorrhea antigen, in the secretory specimen and urine from urogenital system, as an aid in the diagnosis...
Medicine Products: